Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Takayuki Yoshino(University of Tsukuba), Kapil Saxena(Daiichi Sankyo (United States)), Hisato Kawakami(Tohoku University), Kojiro Kobayashi(Daiichi Sankyo (United States)), Zev A. Wainberg(University of California, Los Angeles), Elena Élez(Vall d'Hebron Hospital Universitari), Salvatore Siena(University of Milan), Toshiki Masuishi(Aichi Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Emarjola Bako(BVI (United States)), Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Axel Grothey(Campbell Clinic), Marwan Fakih(City of Hope), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Tomohiro Nishina(Shikoku Cancer Center), Kensei Yamaguchi(Japanese Foundation For Cancer Research), J. Rodríguez(Clinica Universidad de Navarra), Yasuyuki Okuda(Daiichi-Sankyo (Japan)), Gerold Meinhardt(Daiichi Sankyo (United States))
Cited by 159
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k